Given that cellular senescence is now recognized as one of the primary pillars of biological aging, this third mechanism elevates MOTS-c from a metabolic peptide to a potential geroscience intervention
We evaluate at the end of each cycle before deciding whether to repeat, adjust the dose, add a stack partner like TB-500, or transition to a maintenance approach
Follow the written protocol for site selection and rotation [15]
This dead space can waste your precious, high-purity peptide and throw off your dosing
useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established
